We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Automatic Cytometer Tallies Tumor Cells in Blood

By LabMedica International staff writers
Posted on 19 May 2015
Print article
Image: The measuring channel that forms the key component of the PoCyton cytometer is visible on the right-hand side of the image (Photo courtesy of Fraunhofer ICT-IMM).
Image: The measuring channel that forms the key component of the PoCyton cytometer is visible on the right-hand side of the image (Photo courtesy of Fraunhofer ICT-IMM).
Flow cytometry has been used to count cancer cells for many years, but the large instruments are expensive and can only be operated by trained personnel.

Existing flow cytometers are capable of measuring the quantity of tumor cells circulating in the bloodstream but they often cost up to EUR 300,000 and can take up a huge amount of space, equivalent to two washing machines.

Scientists at the Fraunhofer Institute for Chemical Technology (Munich, Germany) have developed the PoCyton cytometer which is cheap to produce, no bigger than a shoebox, and automated. All the PoCyton flow cytometer needs is a sample of the patient's blood, and within a short time the attending physician will know how many tumor cells are circulating in the blood. Cancerous growths release cells into the bloodstream, and their number provides an indication of how effective the therapy has been. If the number of cancerous cells decreases in the course of treatment, it shows that it has been effective.

Flow cytometry works on the following principle: A fluorescent dye is injected into the blood, and the dye molecules bind to the tumor cells, leaving all other cells unmarked. Whereas until now the physician had to add the dye to the blood sample manually, this now takes place automatically in the PoCyton process. The blood is funneled through a narrow focal area, causing all suspended cells to pass one by one in front of a laser spot detector. The light causes the cells to which the dye has attached itself, the tumor cells, to fluoresce, enabling the device to detect and count them. This narrow passage is the key to the PoCyton process.

Michael Bassler, PhD, a senior scientist who helped develop the cytometer, said, “We designed it in such a way that the throughput is 20 times greater than in conventional cytometry. At the same time, its geometry was chosen to ensure that no cells pass in front of one another. In this way the scientists can be sure that the system registers every single object flowing past the detector, and that no cell is hidden behind another. Such errors could have dramatic consequences, because a mere 10 mL sample of blood contains around one billion suspended objects. Of these, only five are circulating tumor cells, even in a severely sick patient.”

Related Links:

Fraunhofer Institute for Chemical Technology


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more